RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China)

Structure/Sequence

Molecular FormulaC22H19FN4O2

InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N

CAS Registry1616493-44-7

264

Clinical Trials associated with Chidamide

NCT06570447

/ RecruitingPhase 2IIT

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Start Date15 May 2025

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

ChiCTR2500099653

/ SuspendedNot ApplicableIIT

A clinical study of mitoxantrone liposome, chidamide combined with lenalidomide in the treatment of angioimmunoblastic T-cell lymphoma (AITL)

Start Date30 Apr 2025

Sponsor / Collaborator-

NCT06930118

/ RecruitingPhase 2IIT

An Exploratory Study Investigating the Combination of Chidamide, Regorafenib, Plus Iparomlimab and Tuvonralimab for the Treatment of Drug-esistant and Efractory Dvanced Colorectal Cancer

Patients with advanced colorectal cancer, particularly those of the pMMR/MSS type, exhibit suboptimal therapeutic responses in the third-line and subsequent treatments. The efficacy of the existing standard treatment regimens is highly restricted. In the CORRECT study, the median overall survival (OS) of regorafenib was 6.4 months, the median progression-free survival (PFS) was 1.9 months, and the objective response rate (ORR) was 1%. In the CONCUR study targeting the Asian population, the median OS of the regorafenib group was 8.8 months, the median PFS was 3.2 months, and the ORR was 4%. In the FRESCO study, the median OS of fruquintinib was 9.3 months, the median PFS was 3.7 months, and the ORR was 4.7%. In the TERRA study, the median OS of trifluridine/tipiracil (TAS-102) was 7.8 months, the median PFS was 2.0 months, and the ORR was 1.1%. The SUNLIGHT study explored the combined treatment modality of TAS-102 plus bevacizumab, where the median OS of the combined regimen was 10.8 months, the median PFS was 5.6 months, and the ORR was 6.1%. Evidently, the therapeutic efficacy of advanced colorectal cancer in the third-line and beyond has plateaued. In recent years, fundamental research has discovered that epigenetic regulation significantly synergizes with anti-angiogenesis and immune checkpoint inhibition therapy. Small-scale clinical explorations have also indicated favorable efficacy and clinical prospects, warranting further investigation. Hence, we contemplate employing the combination of chidamide, regorafenib, and iparomlimab/tuvonralimab to investigate its efficacy and safety in the treatment of advanced colorectal cancer in the third-line and beyond, and to explore novel breakthroughs for refractory colorectal cancer after multiple lines of treatment.
The aim of this study is to assess the efficacy and safety of the combination regimen of chidamide, regorafenib, and iparomlimab/tuvonralimab in patients with advanced colorectal cancer in the third-line and beyond. The study will be conducted at Shanghai Changzheng Hospital. The study drugs, including chidamide, regorafenib, and iparomlimab/tuvonralimab, are all commercially available in China.

Start Date10 Apr 2025

Sponsor / Collaborator

Shanghai Changzheng Hospital

100 Clinical Results associated with Chidamide

100 Translational Medicine associated with Chidamide

100 Patents (Medical) associated with Chidamide

3,116

Literatures (Medical) associated with Chidamide

31 Dec 2025·ANNALS OF MEDICINE

Effect of cold atmospheric plasma on common oral pathogenic microorganisms: a narrative review

Review

Author: Zhang, Hao ; Xin, Jiajun ; Zou, Jiatong ; Li, Yushen ; Dai, Yifei ; Wang, Rui ; Chen, Xiantao ; Liu, Zhihui ; Wang, Bowei

BACKGROUND:

The oral microbiota is a diverse and complex community that maintains a delicate balance. When this balance is disturbed, it can lead to acute and chronic infectious diseases such as dental caries and periodontitis, significantly affecting people's quality of life. Developing a new antimicrobial strategy to deal with the increasing microbial variability and resistance is important. Cold atmospheric plasma (CAP), as the fourth state of matter, has gradually become a hot topic in the field of biomedicine due to its good antibacterial, anti-inflammatory, and anti-tumor capabilities. It is expected to become a major asset in the regulation of oral microbiota.

METHODS:

We conducted a search in PubMed, Medline, and Wiley databases, focusing on studies related to CAP and oral pathogenic microorganisms. We explored the biological effects of CAP and summarized the antimicrobial mechanisms behind it.

RESULTS:

Numerous articles have shown that CAP has a potent antimicrobial effect against common oral pathogens, including bacteria, fungi, and viruses, primarily due to the synergy of various factors, especially reactive oxygen and nitrogen species.

CONCLUSIONS:

CAP is effective against various oral pathogenic microorganisms, and it is anticipated to offer a new approach to treating oral infectious diseases. The future objective is to precisely adjust the parameters of CAP to ensure safety and efficacy, and subsequently develop a comprehensive CAP treatment protocol. Achieving this objective is crucial for the clinical application of CAP, and further research is necessary.

01 Jul 2025·JOURNAL OF HAZARDOUS MATERIALS

Biodegradation and bioaugmentation of the co-contamination of chloramphenicol and microplastics by Exiguobacterium sp. CAP4 isolated from a contaminated plastisphere

Article

Author: Sun, Xiaoxu ; Sun, Weimin ; Luo, Yujiang ; Tan, Zewen ; Huang, Ying

Microplastics (MPs) and antibiotics are newly emerging contaminants that have heavily accumulated in the environment and are a great cause of concern due to their co-contamination. Although the removal and degradation of individual MPs and antibiotics have been studied in various environments, our understanding of how to eliminate the co-contamination of MPs and antibiotics remains poor. In this study, the biodegradation of both micro polyethylene (mPE) and chloramphenicol (CAP) was analyzed in a wastewater sample. Members of the genera Exiguobacterium, Methanospirillum, Methanosaeta, and Candidatus Nitrocosmicus were proposed as biomarkers in plastisphere, which may contribute to the biodegradation of both contaminants. Notably, Exiguobacterium sp. CAP4 was isolated from the plastisphere and exhibited a high potential to degrade both CAP and mPE. Bioaugmentation with Exiguobacterium sp. CAP4 in mPEs and CAP contaminated wastewater facilitated the biodegradation of both mPE and CAP. This work expands the knowledge base regarding the simultaneous elimination of MPs and antibiotics in situ and identifies a promising bacterial strain for both MP and antibiotic biodegradation.

01 Jun 2025·JOURNAL OF PAIN

A Triple combination formulation of an HDAC inhibitor treats chronic pain in rodent spared nerve injury model

Article

Author: Alam, Md Suhail ; Haldar, Kasturi ; Vania Apkarian, A ; Centeno, Maria V

Histone deacetylase inhibitors (HDACi) that modulate epigenetic regulation and are approved for treating rare cancers have, in disease models, also been shown to mitigate neurological conditions, including chronic pain. They are of interest as non-opioid treatments, but achieving long-term efficacy with limited dosing has remained elusive. Here we employ a triple combination formulation (TCF) that includes the pan-HDAC vorinostat (Vo) administered at its FDA-approved daily dosage of 50 mg/Kg, along with the caging agent 2-hydroxypropyl-β-cyclodextrin (HPBCD) and polyethylene glycol (PEG). This formulation enhances plasma and brain exposure of Vo in mice and rat models and shows specific activity in the spared nerve injury (SNI) model of chronic neuropathic pain. TCF (but not HPBCD and PEG) decreased mechanical allodynia for 4 weeks without antagonizing weight, anxiety, or mobility. This was achieved at less than 1% of the total dose of Vo approved for 4 weeks of tumor treatment, decreased RNA levels of two major inflammatory markers (CD11b and GFAP), and reduced proliferation of microglia in the ipsilateral (but not contralateral) spinal cord. A single TCF injection was sufficient for 3-4 weeks of efficacy. Pharmacodynamics suggested pain relief was sustained for weeks after Vo elimination. Doubling Vo in a single TCF injection tripled the response amplitude and remained effective for > 2 months in male rats. Together, these data suggest that the TCF enables single-dose effectiveness with extended action, reduces long-term HDACi dosage, and presents excellent potential to develop as a non-opioid treatment option for chronic pain. PERSPECTIVE: An epigenetic drug formulation (TCF) tested in rat and mouse chronic neuropathic pain models shows adequate and persistent pain relief, engaging spinal cord inflammatory mechanisms.

News (Medical) associated with Chidamide

11 Feb 2025

·cerenoscientific.com

Cereno Scientific’s HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that drug candidate CS014 has completed the first part of two in its Phase I trial in healthy volunteers without any safety concerns. CS014 is a novel histone deacetylase (HDAC) inhibitor with disease-modifying potential being developed for the rare disease idiopathic pulmonary fibrosis (IPF). The Phase I trial intends to evaluate the safety profile of CS014 in humans and is divided into two parts – a single ascending dose part (SAD) and a multiple ascending dose part (MAD). Part two of the trial (MAD) is currently ongoing according to plan and the Phase I trial is expected to be completed in mid-2025. HDACi CS014 has the potential to transform the treatment landscape of IPF. Drug candidate CS014 is a new chemical entity that acts through HDACi with strong vascular remodeling effects and disease-modifying potential as seen in preclinical studies. The potential of the HDACis has been demonstrated through preclinical studies including reversal of pathological remodeling of pulmonary vessels and anti-fibrotic effects in an animal model of PAH, as well as in vivo anti-thrombotic effects across a broad range of vasculature. These properties align with the key disease mechanisms of idiopathic pulmonary fibrosis (IPF) and addresses significant unmet medical needs. The HDACi CS014 has a safety and efficacy profile that is consistent with the significant medical needs remaining despite current IPF treatments. Part one of the Phase I trial of CS014 conducted by our CRO partner CTC in Uppsala explored the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses (SAD) of CS014 in 30 patients. This first part of the trial has successfully been completed with results showing that CS014 exhibited an acceptable safety profile supporting its potential for further clinical development. “We are pleased with the progress of the CS014 Phase I trial and eagerly anticipate its completion in mid-2025. The successful completion of the single ascending dose (SAD) part provides a strong initial validation of HDACi CS014s favorable safety profile,” said Rahul Agrawal, CMO & Head of R&D of Cereno Scientific. “We believe that our novel HDACi CS014 has the potential to become an important treatment meeting high unmet clinical needs in the rare disease IPF. There is a void in the market for safe and well-tolerated novel drugs with a profile addressing the underlying pathophysiology of the IPF disease and its progression. CS014 aims to be a safe, well-tolerated oral drug with disease-modifying capacity and, as such, targets a large market potential,” said Sten R. Sörensen, CEO of Cereno Scientific. The Phase I trial is an open-label, first-in-man trial designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The Phase I trial of CS014 will involve approximately 48 subjects and is expected to be completed mid-2025 whereafter top-line results can be shared after data analysis has been conducted. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS104 HDAC inhibitor CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, under development for idiopathic pulmonary fibrosis (IPF). An ongoing Phase I trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers is expected to conclude in mid-2025. Preclinical studies of HDAC inhibitors show that these drugs can reverse fibrosis in models of IPF. Studies also show that these drugs prevent the pathological remodeling of pulmonary vessels that ultimately leads to pulmonary hypertension in many IPF patients. Preclinical studies of CS014 have demonstrated an effect on reversal of fibrosis and a dose-dependent beneficial effect on pathological vascular remodeling in an established model of PAH. Together, these findings indicate that CS014 has the potential to address the underlying pathophysiology behind the development of IPF. CS014 has demonstrated, in preclinical studies, the ability to regulate platelet activity, local fibrinolysis, and clot stability, helping to prevent thrombosis without increasing the risk of bleeding. This supports CS014's potential to address key unmet needs in IPF patients. Cereno’s HDAC inhibitor portfolio, capitalizing on the principle of epigenetic modulation, comprises Cereno’s lead drug candidate CS1 in Phase II and CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Clinical ResultPhase 2

27 Dec 2024

·cerenoscientific.com

Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that 9 additional patients have entered its Expanded Access Program (EAP) with drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). In total, the EAP now includes 10 patients with the possibility of more patients being included in the coming months. The additional data collected on the patients in the EAP will strengthen the long-term safety and efficacy documentation of CS1 and support regulatory interactions for future clinical trials. “We are very pleased to see the high interest from patients and physicians to continue with the treatment of CS1 after the completed Phase IIa study,” said Sten R. Sörensen, CEO, Cereno Scientific. “From a drug development perspective, it is very valuable for us to be able to collect long-term clinical data on CS1 as we move forward with our plans for the next clinical program.” Drug candidate CS1 has been approved by the FDA for an Expanded Access Program as an extension of the Phase IIa trial in PAH. This program allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through the recently entered collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The EAP, an FDA-approved protocol, enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients supporting required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 732- 33 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS1 Drug candidate CS1 is an HDAC inhibitor (HDACi) that works through epigenetic modulation, being developed as a safe, effective and disease-modifying treatment for the rare disease pulmonary arterial hypertension (PAH). CS1 targets the root mechanism of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. In a Phase IIa study, CS1 successfully met the primary endpoint of safety and tolerability. CS1 further showed compelling positive impact on exploratory clinical efficacy parameters over the 12-week treatment period. The Phase IIa data, together with preclinical data from the HDACi program, directly demonstrates the HDACi program’s dose-dependent positive impact on reverse remodeling in small lung arteries. This provides a basis of assumption that CS1 may act with disease-modifying capacity in PAH. In preclinical cardiovascular disease models, HDAC inhibitors have also shown anti-fibrotic, anti-inflammatory, pulmonary pressure-reducing, and anti-thrombotic effects. CS1’s unique efficacy profile aligns well with the underlying mechanisms of disease that drives the progression of PAH, positioning it to address the critical unmet need for more effective treatment options. The goal of CS1's development is to enhance and extend life for patients with PAH. CS1 is part of Cereno’s HDACi portfolio, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. CS1 has been granted orphan drug status in both the US and EU. CS1 has been approved by the FDA for an Expanded Access Program (EAP) as an extension of the Phase IIa trial in PAH, which enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients. Ten patients are currently enrolled in the program, which allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through a collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The data obtained by the EAP supports required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1Clinical ResultOrphan Drug

20 Dec 2024

·cerenoscientific.com

Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated

20 Dec 2024 07:00Regulatory Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced on 11 November 2024 that the Company has entered into a financing agreement (the “Financing Agreement”) with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Financiers”) securing loan financing of at least 250 MSEK. The Financing Agreement is divided into three components: (i) a cash loan in two tranches totaling 175 MSEK (the “Loan”), (ii) the issue of convertible loans of 75 MSEK to the Financiers (the “Convertibles”), and (iii) the issue without consideration of 5,749,017 warrants to the Financiers (the “Warrants”). The Company today announce that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the transfer of the Warrants to the Financiers’ custody accounts has been initiated. Completed registration and ongoing delivery The Company hereby announces that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the delivery of the Warrants following their connection to Euroclear has been initiated to the custody accounts designated by the Financiers. Main terms of the Convertibles, the Warrants and the Loan The convertible loans of 75 MSEK is represented by convertible promissory notes in the nominal amount of SEK 1 per Convertible. The Convertibles will be due for repayment on 30 April 2026 (the "Maturity Date"), unless Conversion has occurred before that date. The rate of interest on the Convertibles are calculated quarterly and determined at the percentage rate per annum which is the aggregate of STIBOR90 with an additional 11 percentage points. The Company has a right but no obligation to repay the Convertibles, in whole or in part, at any time prior to the Maturity Date without separate costs. In connection with any premature repayment, accrued interest of the amount so prepaid should be paid at the same time. During the term of the Convertibles, the Financiers may demand conversion of all or part of the Convertibles into new B shares in the Company at a conversion price fixed at SEK 6.09. Presuming full conversion of the Convertibles the number of shares in Cereno Scientific will increase by 12,315,270 B-shares and the share capital will increase by SEK 1,231,527 corresponding to a dilution effect of approximately 4.19 per cent of the currently outstanding shares in the company and approximately 4.10 per cent of the currently outstanding votes in the company. In relation to the Warrants, the Financiers are entitled to subscribe for one new B share for each Warrant at a subscription price of SEK 6.82 per B share during the term of the Warrants (up to and including 8 November 2029). Exercise of the Warrants can be done during the whole term of the Warrants. Upon full exercise of the Warrants, the company will receive additional issue proceeds of approximately 39.2 MSEK. Presuming full exercise of the Warrants, the number of shares in Cereno Scientific will increase by 5,749,017 B-shares and the share capital will increase by SEK 574,901.70 corresponding to a dilution effect of approximately 2.00 per cent of the currently outstanding shares in the company and 1.96 per cent of the currently outstanding votes in the company. The Loan is divided into two tranches where Tranche 1 consists of a cash loan of 125 MSEK which was paid out in connection with the signing of the Financing Agreement. Tranche 2 consists of a cash loan of 50 MSEK and is conditional upon the Company having received approval by the FDA regarding CS1 for a phase IIB study or a pivotal study for phase III as well as certain additional financial conditions being fulfilled. The Loan was subject to a customary setup fee amounting to approximately 3,87 per cent of the funding under the Financing Agreement. Parts of Tranche 1 of the Loan have been used to repay the currently outstanding loan to Fenja of approximately 91 MSEK. The interest rate of the Loan under the Financing Agreement is fixed annually starting at the time of payment and bears an annual interest rate set at the percentage rate per annum which is the sum of STIBOR plus 11 percentage points. Repayment of the Loan (both Tranches, if applicable) shall be made on 30 April 2026. Further fundamental information about the Convertibles, the Warrants and the Financing Agreement can be found in the press release of 11 November 2024: Press release | Cereno Scientific. For further information, please contact: Eva Jagenheim, CFO Email: eva.jagenheim@cerenoscientific.com Phone: +46 70 492 35 63 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information at www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Clinical Result

100 Deals associated with Chidamide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Chidamide	L01XX	DB06334

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	24 Apr 2024
Adult T-Cell Leukemia-Lymphoma	Japan	Meiji Seika Pharma Co., Ltd.	23 Jun 2021
Breast Cancer	China	Shenzhen Chipscreen Biosciences Co., Ltd.	20 Nov 2019
Peripheral T-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	23 Dec 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Shenzhen Chipscreen Biosciences Co., Ltd.	27 Nov 2024
Metastatic Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Microsatellite Instability cancer	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Brain metastases	Phase 3	United States	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	United States	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Japan	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	Japan	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Australia	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	Australia	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Austria	HUYA Bioscience International LLC	12 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05659992 (Pubmed \| Front Immunol)	Phase 2	Acute Myeloid Leukemia DNMTs \| HDACs	40	Chidamide + CAG + Venetoclax-Azacitidine	vjsxawdjtm(pszmnovbje) = qkqsastumb lamhoohepq (kkpmqeluzy, 55.9 - 84.8) View more	Positive	26 Feb 2025
ChiCTR2200058431 (P-henomS/SCOG-P002, ASCO_GI2025) Manual	Phase 2	Pancreatic Cancer Second line	16	Chidamide + Envafolimab + S-1	cfwagmppap(zcjyrywlld) = aocvnhoqmt dpzdeaqmla (yxgcklaroa ) View more	Positive	23 Jan 2025
NCT04661943 (4490Chidamide, ASH2024)	Phase 2	Hepatitis B \| Diffuse Large B-Cell Lymphoma Maintenance	95	Chidamide maintenance therapy	kocyxsexga(ekidxbrptp) = neutropenia, anemia, thrombocytopenia mkkaduisjg (ukexwmefue )	Positive	09 Dec 2024
NCT04661943 (4490Chidamide, ASH2024)	Phase 2	Hepatitis B \| Diffuse Large B-Cell Lymphoma Maintenance	95	Chidamide (Observation group)		Positive	09 Dec 2024
NCT05566054 (ASH2024)	Phase 2	Acute Myeloid Leukemia	-	VAC regimen	asujtmsdrh(ooflnmedce) = eczhhwwqfr fhdvdkakfh (twdlyiekhi ) View more	-	07 Dec 2024
NCT05566054 (ASH2024)	Phase 2	Acute Myeloid Leukemia	-	VA regimen	asujtmsdrh(ooflnmedce) = nkndlhalnu fhdvdkakfh (twdlyiekhi ) View more	-	07 Dec 2024
ASH2024	Not Applicable	Relapsing acute myeloid leukemia	-	Chidamide	tzsmztismc(dwaipnolms) = one patient experienced grade 3/4 diarrhea dkvsqoliyi (tigrxnbjqh ) View more	-	07 Dec 2024
NCT02718066 (HBI-8000-302, SITC2024) Manual	Phase 1/2	Melanoma	39	HBI-8000 + Nivolumab	ddaqtrtsbq(zdbaphlcne) = hpozsvorso patelenhwj (jevnfnfntq ) View more	Positive	05 Nov 2024
NCT02955589 (Phase 2B Study, CTgov)	Phase 2	Adult T-Cell Leukemia-Lymphoma	23	HBI-8000	ozsafltgkx = pkjesxqqqi aagrdqllyt (fkfjgmiuul, acwzwlyxfm - pervdhwpcq) View more	-	19 Sep 2024
NCT05411380 (ESMO2024) Manual	Phase 2	Hormone receptor positive HER2 negative breast cancer HER2 Negative \| Hormone Receptor Positive	43	Tucidinostatcapecitabine	btjuazdcbn(ypckiqzngy) = zkgullboac onyimquguj (pmuauglafr ) View more	Positive	16 Sep 2024
ChiCTR2400080783 (B-Enefits/SCOG-B001, ESMO2024) Manual	Phase 2	Biliary Tract Neoplasms First line	32	Envafolimabchidamide	ypfarlplzb(bmluicfkyu) = sxqvtuqvgy hjgwfqrmpe (dkcafsberc ) View more	Positive	16 Sep 2024
NCT03268889 (Pubmed \| Front Immunol) Manual	Not Applicable	Immunoblastic Lymphadenopathy	66	Chidamide + CHOP	emtiqwvgph(kdvjijmcfk) = rmmhnqggkc sriultgbru (foicisgbai ) View more	Positive	20 Aug 2024
NCT03268889 (Pubmed \| Front Immunol) Manual	Not Applicable	Immunoblastic Lymphadenopathy	66	CHOP alone	emtiqwvgph(kdvjijmcfk) = nejbokvwls sriultgbru (foicisgbai ) View more	Positive	20 Aug 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chidamide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation